Leo

LEO Pharma is a global pharmaceutical company headquartered in Denmark, dedicated to advancing the standard of care in medical dermatology and thrombosis. Founded in 1908, the company is majority-owned by the LEO Foundation and focuses on developing innovative treatments for skin conditions such as psoriasis, atopic dermatitis, and eczema, as well as critical care therapies for blood clots. Its portfolio includes well-known brands like Adtralza (tralokinumab), Enstilar, and Innohep. LEO Pharma operates in more than 100 countries and maintains a robust pipeline of both small molecules and biologics. The company is currently undergoing a strategic transformation to strengthen its position as a global leader in medical dermatology.